Citius Oncology (NASDAQ:CTOR) Releases Earnings Results

Citius Oncology (NASDAQ:CTOR) announced its quarterly earnings results on Tuesday. The company reported ($0.06) EPS for the quarter, Zacks reports.

Citius Oncology Price Performance

Shares of CTOR opened at $1.27 on Wednesday. The business has a 50-day moving average of $1.39 and a 200-day moving average of $1.90. Citius Oncology has a 1 year low of $0.55 and a 1 year high of $6.19. The company has a market capitalization of $106.06 million, a price-to-earnings ratio of -4.54 and a beta of 2.98. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.35 and a quick ratio of 0.02.

Analyst Ratings Changes

Several research firms have commented on CTOR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Oncology in a research report on Monday. Citigroup upgraded shares of Citius Oncology from a “hold” rating to a “buy” rating in a report on Tuesday, September 23rd. Finally, Maxim Group raised shares of Citius Oncology from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Tuesday, September 23rd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Citius Oncology presently has a consensus rating of “Hold” and an average price target of $6.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Citadel Advisors LLC bought a new position in Citius Oncology during the third quarter worth $36,000. Bank of America Corp DE raised its position in shares of Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after acquiring an additional 8,411 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Citius Oncology by 179.0% in the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock valued at $249,000 after purchasing an additional 36,758 shares during the period. Jane Street Group LLC bought a new stake in shares of Citius Oncology during the 2nd quarter valued at about $465,000. Finally, Armistice Capital LLC bought a new stake in shares of Citius Oncology during the 3rd quarter valued at about $15,582,000. Institutional investors and hedge funds own 70.52% of the company’s stock.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.